Cryoablation with drug-loaded bead embolization in the treatment of unresectable hepatocellular carcinoma: safety and efficacy analysis
PDF | HTML | How to cite
Metrics: PDF 1802 views | HTML 1989 views | ?
Jian-Ying Zeng1, Xiang-Hao Piao2, Zhong-Yuan Zou2, Qing-Feng Yang2, Zi-Lin Qin3, Ji-Bing Chen1, Liang Zhou4, Li-Zhi Niu4 and Jian-Guo Liu4
1Central Laboratory, Affiliated Fuda Cancer Hospital, Jinan University, Guangzhou 510665, P.R. China
2Department of Intervention, Affiliated Fuda Cancer Hospital, Jinan University, Guangzhou 510665, P.R. China
3School of Medicine, Jinan University, Guangzhou 510632, P.R. China
4Department of Surgical Oncology, Affiliated Fuda Cancer Hospital, Jinan University, Guangzhou 510665, P.R. China
Xiang-Hao Piao, email: [email protected]
Keywords: hepatocellular carcinoma; transarterial chemoembolization; cryoablation; hepasphere microsphere; doxorubicin
Received: November 02, 2017 Accepted: January 03, 2018 Published: January 08, 2018
This study aimed to explore the efficacy and safety of drug-eluting bead (DEB) embolization (DEB-TACE) when combined with cryoablation in the treatment of unresectable hepatocellular carcinoma (HCC). The study was a single-center randomized controlled trial comprised of 60 patients with HCC conducted between August 2015 and October 2017. The patients were randomly divided into two groups: DEB-TACE combined with cryoablation (DEB-TACE-Cryo group) or cryoablation alone (Cryo group). Inter-group differences in overall survival, progression-free survival, and adverse reactions were assessed. The operative success rates were 82.7% and 77.4% in the DEB-TACE-Cryo group and Cryo group, respectively, with no operative mortality. The overall survival and progression-free survival in the DEB-TACE-Cryo group were significantly higher than those in the Cryo group (16.8 months vs.13.4 months, P = 0.0493; 8.1 months vs. 6.0 months, P = 0.0089, respectively). The postoperative complications in the two groups were rated as grade 1 or grade 2, according to guidelines set by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE V4.0). We demonstrated that DEB-TACE combined with cryoablation was effective, well tolerated, and had a low complication rate. Therefore, this combination therapy may be a better choice for the treatment of unresectable hepatocellular carcinoma.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.